Literature DB >> 22258710

18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials.

Thida Win1, Tryphon Lambrou, Brian F Hutton, Irfan Kayani, Nicholas J Screaton, Joanna C Porter, Toby M Maher, Raymondo Endozo, Robert I Shortman, Pauline Lukey, Ashley M Groves.   

Abstract

PURPOSE: Noninvasive markers of disease activity in patients with idiopathic pulmonary fibrosis (IPF) are lacking. We performed this study to investigate the reproducibility of pulmonary (18)F-FDG PET/CT in patients with IPF.
METHODS: The study group comprised 13 patients (11 men, 2 women; mean age 71.1 ± 9.9 years) with IPF recruited for two thoracic (18)F-FDG PET/CT studies performed within 2 weeks of each other. All patients were diagnosed with IPF in consensus at multidisciplinary meetings as a result of typical clinical, high-resolution CT and pulmonary function test features. Three methods for evaluating pulmonary (18)F-FDG uptake were used. The maximal (18)F-FDG pulmonary uptake (SUVmax) in the lungs was determined using manual region-of-interest placement. An (18)F-FDG uptake intensity histogram was automatically constructed from segmented lungs to evaluate the distribution of SUVs. Finally, mean SUV was determined for volumes-of-interest in pulmonary regions with interstitial lung changes identified on CT scans. Processing included correction for tissue fraction effects. Bland-Altman analysis was performed and interclass correlation coefficients (ICC) were determined to assess the reproducibility between the first and second PET scans, as well as the level of intraobserver and interobserver agreement.
RESULTS: The mean time between the two scans was 6.3 ± 4.3 days. The interscan ICCs for pulmonary SUVmax analysis and mean SUV corrected for tissue fraction effects were 0.90 and 0.91, respectively. Intensity histograms were different in only 1 of the 13 paired studies. Intraobserver agreement was also excellent (0.80 and 0.85, respectively). Some bias was observed between observers, suggesting that serial studies would benefit from analysis by the same observer.
CONCLUSION: This study demonstrated that there is excellent short-term reproducibility in pulmonary (18)F-FDG uptake in patients with IPF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22258710     DOI: 10.1007/s00259-011-1986-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  34 in total

1.  Restaging: should we percist without pattern recognition?

Authors:  Michael S Hofman; Rodney J Hicks
Journal:  J Nucl Med       Date:  2010-11-15       Impact factor: 10.057

2.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

Review 3.  Role of functional imaging in the management of lymphoma.

Authors:  Bruce D Cheson
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

4.  Pulmonary tissue attenuation with computed tomography: comparison of inspiration and expiration scans.

Authors:  P J Robinson; L Kreel
Journal:  J Comput Assist Tomogr       Date:  1979-12       Impact factor: 1.826

5.  11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Authors:  Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman
Journal:  Lancet Neurol       Date:  2010-02-26       Impact factor: 44.182

Review 6.  Idiopathic pulmonary fibrosis.

Authors:  T J Gross; G W Hunninghake
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

7.  (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials.

Authors:  James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Ash Rafique; Michael Farkouh; Valentin Fuster; Zahi A Fayad
Journal:  J Am Coll Cardiol       Date:  2007-08-13       Impact factor: 24.094

8.  Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.

Authors:  Heather A Jacene; Sophie Leboulleux; Shingo Baba; Daniel Chatzifotiadis; Behnaz Goudarzi; Oleg Teytelbaum; Karen M Horton; Ihab Kamel; Katarzyna J Macura; Hua-Ling Tsai; Jeanne Kowalski; Richard L Wahl
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

9.  Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations.

Authors:  James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Cathy Anne Pinto; Christopher Tong; Ash Rafique; Richard Hargeaves; Michael Farkouh; Valentin Fuster; Zahi A Fayad
Journal:  J Nucl Med       Date:  2008-05-15       Impact factor: 10.057

10.  Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography.

Authors:  Adrianus J de Langen; Bianca Klabbers; Mark Lubberink; Ronald Boellaard; Marieke D Spreeuwenberg; Ben J Slotman; Remco de Bree; Egbert F Smit; Otto S Hoekstra; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10-18       Impact factor: 9.236

View more
  20 in total

1.  Aerobic Glycolysis and the Warburg Effect. An Unexplored Realm in the Search for Fibrosis Therapies?

Authors:  Toby M Maher
Journal:  Am J Respir Crit Care Med       Date:  2015-12-15       Impact factor: 21.405

2.  Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models.

Authors:  Pauline Désogère; Luis F Tapias; Lida P Hariri; Nicholas J Rotile; Tyson A Rietz; Clemens K Probst; Francesco Blasi; Helen Day; Mari Mino-Kenudson; Paul Weinreb; Shelia M Violette; Bryan C Fuchs; Andrew M Tager; Michael Lanuti; Peter Caravan
Journal:  Sci Transl Med       Date:  2017-04-05       Impact factor: 17.956

Review 3.  Noninvasive imaging of experimental lung fibrosis.

Authors:  Yong Zhou; Huaping Chen; Namasivayam Ambalavanan; Gang Liu; Veena B Antony; Qiang Ding; Hrudaya Nath; Janet F Eary; Victor J Thannickal
Journal:  Am J Respir Cell Mol Biol       Date:  2015-07       Impact factor: 6.914

4.  PET/CT and inflammatory mediators in systemic sclerosis-associated interstitial lung disease.

Authors:  Andréa L Bastos; Gilda A Ferreira; Marcelo Mamede; Eliane V Mancuzo; Mauro M Teixeira; Flávia P S T Santos; Cid S Ferreira; Ricardo A Correa
Journal:  J Bras Pneumol       Date:  2022-06-06       Impact factor: 2.800

5.  Matrix Metalloproteinase-Targeted Imaging of Lung Inflammation and Remodeling.

Authors:  Reza Golestani; Mahmoud Razavian; Yunpeng Ye; Jiasheng Zhang; Jae-Joon Jung; Jakub Toczek; Kiran Gona; Hye-Yeong Kim; Jack A Elias; Chun Geun Lee; Robert J Homer; Mehran M Sadeghi
Journal:  J Nucl Med       Date:  2016-07-28       Impact factor: 10.057

6.  Noninvasive monitoring of pulmonary fibrosis by targeting matrix metalloproteinases (MMPs).

Authors:  Yan Cai; Lei Zhu; Fan Zhang; Gang Niu; Seulki Lee; Shioko Kimura; Xiaoyuan Chen
Journal:  Mol Pharm       Date:  2013-05-08       Impact factor: 4.939

7.  Apoptotic PET Imaging of Rat Pulmonary Fibrosis with Small-Molecule Radiotracer.

Authors:  Ying Xiong; Dahong Nie; Shaoyu Liu; Hui Ma; Shu Su; Aixia Sun; Jing Zhao; Zhanwen Zhang; Xianhong Xiang; Ganghua Tang
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

Review 8.  Quantification of Lung PET Images: Challenges and Opportunities.

Authors:  Delphine L Chen; Joseph Cheriyan; Edwin R Chilvers; Gourab Choudhury; Christopher Coello; Martin Connell; Marie Fisk; Ashley M Groves; Roger N Gunn; Beverley F Holman; Brian F Hutton; Sarah Lee; William MacNee; Divya Mohan; David Parr; Deepak Subramanian; Ruth Tal-Singer; Kris Thielemans; Edwin J R van Beek; Laurence Vass; Jeremy W Wellen; Ian Wilkinson; Frederick J Wilson
Journal:  J Nucl Med       Date:  2017-01-12       Impact factor: 10.057

Review 9.  Recent advances in understanding idiopathic pulmonary fibrosis.

Authors:  Cécile Daccord; Toby M Maher
Journal:  F1000Res       Date:  2016-05-31

10.  Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients.

Authors:  Thida Win; Benjamin A Thomas; Tryphon Lambrou; Brian F Hutton; Nicholas J Screaton; Joanna C Porter; Toby M Maher; Raymondo Endozo; Robert I Shortman; Asim Afaq; Pauline Lukey; Peter J Ell; Ashley M Groves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-14       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.